Merck & Co., Inc.

MRK
Pharmaceutical preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance SheetCash Flow
Period
Annual Quarterly
Order

39 more quarters with Pro

Merck & Co., Inc. back to 2009, every line as filed.

Create a free account
USD ($)
$ in Millions 		Jun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023Mar 31, 2023Sep 30, 2022Jun 30, 2022Mar 31, 2022Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018Sep 30, 2017Jun 30, 2017Mar 31, 2017Sep 30, 2016Jun 30, 2016Mar 31, 2016Sep 30, 2015Jun 30, 2015Mar 31, 2015Sep 30, 2014Jun 30, 2014Mar 31, 2014Sep 30, 2013Jun 30, 2013Mar 31, 2013Jun 30, 2012Mar 31, 2012Sep 30, 2011Jun 30, 2011Mar 31, 2011Sep 30, 2010Jun 30, 2010Mar 31, 2010Sep 30, 2009Jun 30, 2009
Cash Flows from Operating Activities
                                                   
Net (loss) income
$ (1,337)
$ (4,243)
$ 5,787
$ 4,428
$ 5,085
$ 3,161
$ 5,461
$ 4,767
$ 4,750
-
-
-
Net (loss) income
-
-
-
-
-
-
-
-
-
(5,972)
2,825
3,253
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
                                                   
Amortization
984
931
622
601
597
633
614
473
562
477
543
460
Depreciation
599
581
532
518
502
553
518
511
452
426
448
499
Depreciation and amortization
-
-
-
-
-
-
-
-
-
-
-
-
Intangible asset impairment charges
-
-
-
-
-
-
-
-
13
-
-
887
Income from investments in equity securities, net
(242)
(168)
(373)
(100)
(90)
31
(56)
(143)
33
175
(450)
371
Charge for the acquisition of Harpoon Therapeutics, Inc.
-
-
-
-
-
-
-
656
-
-
-
-
Charges for research and development asset acquisitions
5,271
8,540
-
-
0
-
-
0
-
-
1,192
-
Charge for the acquisition of Eyebiotech Limited
-
-
-
-
-
1,350
-
-
-
-
-
-
Charge for the acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical
-
-
-
-
-
750
-
-
-
-
-
-
Charge for the acquisition of Harpoon Therapeutics, Inc.
-
-
-
-
-
-
656
-
-
-
-
-
Charge for the acquisition of Prometheus Biosciences, Inc.
-
-
-
-
-
-
-
-
-
10,217
-
-
Charge for the acquisition of Pandion Therapeutics, Inc.
-
-
-
-
-
-
-
-
-
-
-
-
Charge for future payments related to collaboration license options
-
-
-
-
-
-
-
-
-
-
-
-
Charge for collaboration termination
-
-
-
-
-
-
-
-
-
-
-
-
Foreign exchange losses related to Venezuela
-
-
-
-
-
-
-
-
-
-
-
-
Gain on divestiture of certain ophthalmic products
-
-
-
-
-
-
-
-
-
-
-
-
Gain on AstraZeneca option exercise
-
-
-
-
-
-
-
-
-
-
-
-
Intangible asset impairment charges
-
-
-
-
-
-
-
-
-
-
-
-
Equity income from affiliates
-
-
-
-
-
-
-
-
-
-
-
-
Dividends and distributions from equity affiliates
-
-
-
-
-
-
-
-
-
-
-
-
Gain on AstraZeneca asset option exercise
-
-
-
-
-
-
-
-
-
-
-
-
Deferred income taxes
(544)
(315)
(212)
(448)
(186)
(401)
(181)
(51)
(336)
(355)
(277)
(661)
Share-based compensation
298
185
204
216
195
195
203
176
164
169
145
139
Other
(81)
20
(51)
335
109
437
91
83
(99)
202
(197)
393
Net changes in assets and liabilities
423
(1,613)
1,314
(2,259)
(3,712)
2,582
(1,012)
(3,382)
2,177
(1,636)
(2,890)
263
Net changes in assets and liabilities
-
-
-
-
-
-
-
-
-
-
-
-
Special, merger and acquisition-related charges and payments
-
-
-
-
-
-
-
-
-
-
-
-
Changes in assets and liabilities:
                                                   
Accounts receivable
-
-
-
-
-
-
-
-
-
-
-
-
Inventories
-
-
-
-
-
-
-
-
-
-
-
-
Prepaid expenses and other assets
-
-
-
-
-
-
-
-
-
-
-
-
Accounts payable
-
-
-
-
-
-
-
-
-
-
-
-
Other liabilities
-
-
-
-
-
-
-
-
-
-
-
-
Net Cash Provided by Operating Activities
5,370
3,918
7,822
3,293
2,500
9,291
5,637
3,090
7,717
3,704
1,339
-
Net Cash Provided by Operating Activities of Continuing Operations
-
-
-
-
-
-
-
-
-
-
-
5,602
Cash Flows from Investing Activities
                                                   
Capital expenditures
(893)
(991)
(987)
(764)
(1,328)
(783)
(791)
(861)
(902)
(965)
(1,007)
(1,126)
Purchases of securities and other investments
(148)
(374)
-
(612)
(595)
-
(49)
(15)
(117)
(25)
(562)
(5)
Proceeds from sales of securities and other investments
1,303
0
575
601
456
50
60
260
704
285
500
335
Acquisition of Terns Pharmaceuticals, Inc., net of cash acquired
(5,842)
-
-
-
-
-
-
0
-
-
(1,327)
-
Acquisition of Prometheus Biosciences, Inc., net of cash acquired
-
-
-
-
-
-
-
-
(10,705)
-
-
-
Acquisition of Cidara Therapeutics, Inc., net of cash acquired
-
(8,779)
-
-
0
-
-
(746)
10,705
(10,705)
-
(121)
Acquisition of Eyebiotech Limited, net of cash acquired
-
-
-
-
-
(1,344)
-
-
-
-
-
-
Acquisition of Elanco Animal Health Incorporated aqua business
-
-
-
-
-
(1,301)
-
-
-
-
-
-
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical
-
-
-
-
-
(700)
-
-
-
-
-
-
Dispositions of property and equipment
-
-
-
-
-
-
-
-
-
-
-
-
Contributions to benefit-related trusts
-
-
-
-
-
-
-
-
-
-
-
-
Dispositions of businesses, net of cash divested
-
-
-
-
-
-
-
-
-
-
-
-
Proceeds from AstraZeneca option exercise
-
-
-
-
-
-
-
-
-
-
-
-
(Increase) decrease in restricted assets
-
-
-
-
-
-
-
-
-
-
-
-
Purchases of short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
Maturities of short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
Other
(22)
(66)
129
5
(20)
233
(289)
(14)
(19)
(33)
37
(45)
Net Cash Used in Investing Activities
(5,602)
(10,210)
(283)
(770)
(1,487)
(3,845)
(1,069)
(1,376)
(334)
(11,443)
(2,359)
-
Net Cash Used in Investing Activities of Continuing Operations
-
-
-
-
-
-
-
-
-
-
-
(962)
Cash Flows from Financing Activities
                                                   
Proceeds from term loan
6,000
-
-
-
-
-
-
-
-
-
-
-
Payments on term loan
(6,000)
-
-
-
-
-
-
-
-
-
-
-
Proceeds from issuance of debt
5,956
-
5,962
-
-
(1)
3,600
-
(7)
5,946
-
-
Cash dividends paid to preferred shareholders
-
-
-
-
-
-
-
-
-
-
-
-
Net change in short-term borrowings
-
1,061
15
48
-
-
-
-
-
1,937
-
-
Payments on debt
(5)
(1,140)
(1)
-
(2,500)
-
-
(751)
(1)
(1,750)
(1)
(1,000)
Dividends paid to stockholders
(2,144)
(2,105)
(2,031)
(2,077)
(2,050)
(1,953)
(1,986)
(1,950)
(1,855)
(1,885)
(1,853)
(1,747)
Distribution from Organon & Co.
-
-
-
-
-
-
-
-
-
-
-
-
Purchases of treasury stock
(757)
(874)
(1,323)
(1,345)
(1,164)
(444)
(251)
(122)
(466)
(338)
(149)
-
Proceeds from exercise of stock options
43
157
14
12
19
5
73
87
7
82
30
10
Other
(270)
(80)
2
(194)
(60)
(32)
(220)
(78)
(10)
(234)
(81)
35
Net Cash Used in Financing Activities
1,762
(2,981)
2,638
(3,556)
(5,755)
(2,425)
1,216
(2,814)
(4,269)
3,758
(2,054)
-
Effect of Exchange Rate Changes on Cash and Cash Equivalents
-
-
-
-
-
-
-
-
-
-
-
-
Net Increase (Decrease) in Cash and Cash Equivalents
-
-
-
-
-
-
-
-
-
-
-
-
Net Cash Used in Financing Activities of Continuing Operations
-
-
-
-
-
-
-
-
-
-
-
(2,702)
Cash Flows from Discontinued Operations
                                                   
Net cash provided by operating activities
-
-
-
-
-
-
-
-
-
-
-
-
Net cash used in investing activities
-
-
-
-
-
-
-
-
-
-
-
-
Net cash used in financing activities
-
-
-
-
-
-
-
-
-
-
-
-
Net Cash Flows Provided by Discontinued Operations
-
-
-
-
-
-
-
-
-
-
-
-
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash
(37)
(19)
10
374
156
294
(82)
(138)
(157)
(93)
87
(412)
Net Decrease in Cash, Cash Equivalents and Restricted Cash
$ 1,493
$ (9,292)
$ 10,187
$ (659)
$ (4,586)
$ 3,315
$ 5,702
$ (1,238)
$ 2,957
$ (4,074)
$ (2,987)
$ 1,526